PITCH
Pitch , the collaborative presentation platform for modern teams, today announced that it has raised an $85 million Series B funding round led by Lakestar and Tiger Global, and joined by existing Pitch investors Index Ventures and Thrive Capital.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005667/en/
Six months after launching to the public, the Series B investment comes at a time of significant growth and momentum for Pitch. To date, tens of thousands of teams have opened 125,000 workspaces on Pitch, including top companies like Intercom, Superhuman and Notion.
“Our mission at Pitch is to enable every team’s best thinking,” said Christian Reber, Founder & CEO of Pitch. “It’s been six months since we launched to the world, and tens of thousands of teams have already discovered how easy it is to create, collaborate on and deliver beautiful presentations on Pitch. We’re thrilled to have two world-class partners in Tiger Global and Lakestar onboard as we pursue our vision to build the first complete platform for presentations.”
A new kind of platform
To accelerate its momentum in the year ahead, Pitch plans to use the new funding to develop its core technology and product, grow its global team, and extend its software platform across the entire presentation workflow.
- A publishing and content ecosystem: Pitch is building a dedicated home for publishing and exchanging presentations and templates. In this new ecosystem, users will be able to discover content from top creators and brands, and publish their own work directly to public profile pages. In the upcoming weeks, Pitch will launch the first of these pages for a select group of creators, and will open up access to all users later this year.
- Advanced presentation analytics: Pitch is building new integrated solutions for users to better distribute presentations and monitor performance. Rolling out in multiple stages this summer, these new features will enable secure sharing and advanced analytics within Pitch, and will give users detailed insights into the reach and readership of a presentation, engagement levels on specific slides, and more.
- Narrative recording and playback: Pitch is building new ways to highlight, record, and play back presentations in any context. Designed for a more remote, asynchronous world of work, these tools will ensure presenters and recipients can engage across an expanded range of meeting formats and team workflows. These tools are currently in beta, and will be rolled out in stages to users in the coming months.
“The exciting vision that Christian and the team at Pitch have is beyond just being a superior alternative to legacy presentation software," said Stephen Nundy, Partner at Lakestar. "A reimagining of the entire workflow surrounding presentations is very much overdue, and when coupled with the ability to harness new data and media integrations, Pitch will lead the way in changing how stories are told. I’m very proud to be joining the board of a European company with its sights set on a truly global opportunity.”
“We are incredibly impressed by the quality of Pitch’s offering today and Christian’s vision for the future. Pitch will be a true productivity platform, and we are excited to become investors in this special company,” says John Curtius, Partner at Tiger Global.
Pitch offers both free and paid plans for teams of all sizes. With Pitch Pro, teams unlock access to unlimited storage, video uploads, version history, and advanced permissioning for $10 per member per month.
About Pitch
Pitch is the collaborative presentation software for modern teams. With a focus on real-time collaboration, smart workflows, and intuitive design features, Pitch makes it fast and delightful for teams to create and deliver beautiful presentations, and easy for anyone to find inspiration from templates crafted by experts. Tens of thousands of teams have made the switch to Pitch, including top brands like Intercom, Superhuman, and Notion. Founded in 2018 by the team behind Wunderlist, and powered by a team of over 100 thinkers, makers, and storytellers, Pitch has raised over $135 million to date. To learn more and create a free account, visit pitch.com
About Lakestar
Lakestar is one of Europe's leading venture capital firms investing in technology companies led by exceptional entrepreneurs. The team’s early investments included Skype, Spotify, Facebook and airbnb. Since raising a first fund in 2013, Lakestar manages an aggregated volume of over EUR 1bn across three early stage funds, and more recently a growth fund. The company has expanded and broadened its portfolio and holds investments in the likes of Opendoor, Oscar, GYG, Glovo, Sennder, Eigen, FiveAI, Revolut and Hometogo to name a few. Lakestar has presence in Berlin, Zurich and London. Lakestar helps companies to identify new markets and expand into them rapidly, with a focus on the US and Europe. The team advises and supports portfolio companies in business development, recruitment, technology and marketing. The investments range from early stage companies to those in their growth stage. Visit us on LinkedIn and our website.
About Tiger Global Management
Tiger Global Management is a leading global technology investment firm with over $60 billion under management. The firm focuses on private and public companies in the internet, software, and financial technology sectors. Since 2001, Tiger Global has invested in hundreds of companies across more than 30 countries, including investments ranging from Series A to pre-IPO. The firm aims to partner with dynamic entrepreneurs operating market-leading companies in its core focus areas. Tiger Global’s investments have included JD.com, UiPath, Stripe, Databricks, Bytedance, Snowflake, Facebook, Alibaba, Procore, Chime, Blend, Peloton, Attentive, LinkedIn, Flipkart, and Toast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005667/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release
ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom